Cipla Limited CIPLA

Latest filings

• Routine15 24 Sept, 19:07 · BSE
  In terms of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 24th September, 2026 has allotted 12,168 ....
• Routine15 24 Sept, 19:03 · NSE
  Allotment of 12168 Shares.
• Management change38 22 Sept, 22:57 · NSE
  Change in Senior Management Personnel.
• General25 18 Sept, 17:32 · BSE
  Please find enclosed disclosure on ESG Rating.
• General25 18 Sept, 17:32 · NSE
  Intimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
• General25 3 Sept, 20:13 · NSE
  A press release dated September 03, 2026, titled "Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US".
• M&A76 3 Sept, 16:43 · BSE
  Cipla Ltd - 500087 - Notice To Shareholders And Creditors In Accordance With NCLT Order Dated 18Th August, 2026 Regarding Merger Of Inzpera Healthsciences Limited With The Company
• Routine15 2 Sept, 19:57 · BSE
  Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Newspaper Publication
• Approval70 31 Aug, 15:53 · NSE
  A press release dated August 31, 2026, titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)".
• General25 31 Aug, 15:42 · BSE
  Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Shown 15 minutes after publication. Real time with Pro.

Upcoming corporate actions

No announced actions in the next 60 days.